Scale ready partner Lycera is a small biopharma with 11-50 employees and modest revenue (10-25M) supported by around 30M in funding, indicating readiness for external scale-up resources. The company focuses on small molecule therapies for autoimmune diseases and cancer, with expertise in immune modulation and distinct mechanism areas. This positions Lycera as a strong candidate for CDMO and CRO partnerships to accelerate preclinical-to-clinical milestones and GMP manufacturing.

Immune modulators pipeline Their active portfolio spans immune metabolism, cell signaling, and immune cell differentiation, offering opportunities for licensing or co-development with larger pharma to complement existing assets. Partners can propose mechanism-specific collaborations or disease-area co-development agreements aligned with Lycera's scientific focus and ability to generate proof-of-concept data.

Strategic partnerships potential Lycera reports established global relationships with leading chemists, scientists, and clinical researchers, a valuable asset for joint development programs and investigator-initiated trials. These networks can reduce diligence risk and accelerate partnerships by providing ready access to external experts and trial sites.

Exit history advantage Historically, Lycera was acquired by Celgene in 2015, with Celgene maintaining option rights to acquire Lycera upon milestones, signaling pharma-level interest and potential exit paths for strategic partners or buyers. This track record can support conversations around licensing deals or strategic collaborations with large pharmaceutical companies.

Growth capital alignment With revenue in the 10-25M range and around 30M in funding, Lycera is positioned for growth and may seek additional capital to scale its programs. This creates opportunities for strategic investment, corporate partnerships, or grant-funded collaborations to support ongoing development and potential commercialization.